<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Alzheimers Dis</journal-id><journal-id journal-id-type="publisher-id">JAD</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><issn-l>1387-2877</issn-l><publisher><publisher-name>IOS Press</publisher-name><publisher-loc>Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27163830</article-id><article-id pub-id-type="pmc">4955514</article-id><article-id pub-id-type="publisher-id">JAD160258</article-id><article-id pub-id-type="doi">10.3233/JAD-160258</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Early Postmenopausal Transdermal 17&#x003b2;-Estradiol Therapy and Amyloid-&#x003b2; Deposition</article-title><alt-title alt-title-type="left-running-head">K. Kantarci et al.</alt-title><alt-title alt-title-type="right-running-head">Postmenopausal Hormone Therapy and A&#x003b2; Deposition</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kantarci</surname><given-names>Kejal</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>Val J.</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Lesnick</surname><given-names>Timothy G.</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Tosakulwong</surname><given-names>Nirubol</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Bailey</surname><given-names>Kent R.</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Fields</surname><given-names>Julie A.</given-names></name><xref ref-type="aff" rid="aff3">c</xref></contrib><contrib contrib-type="author"><name><surname>Shuster</surname><given-names>Lynne T.</given-names></name><xref ref-type="aff" rid="aff4">d</xref></contrib><contrib contrib-type="author"><name><surname>Zuk</surname><given-names>Samantha M.</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Senjem</surname><given-names>Matthew L.</given-names></name><xref ref-type="aff" rid="aff5">e</xref></contrib><contrib contrib-type="author"><name><surname>Mielke</surname><given-names>Michelle M.</given-names></name><xref ref-type="aff" rid="aff2">b</xref><xref ref-type="aff" rid="aff6">f</xref></contrib><contrib contrib-type="author"><name><surname>Gleason</surname><given-names>Carey</given-names></name><xref ref-type="aff" rid="aff7">g</xref></contrib><contrib contrib-type="author"><name><surname>Jack</surname><given-names>Clifford R.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Rocca</surname><given-names>Walter A.</given-names></name><xref ref-type="aff" rid="aff2">b</xref><xref ref-type="aff" rid="aff6">f</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Virginia M.</given-names></name><xref ref-type="aff" rid="aff8">h</xref></contrib><aff id="aff1"><label>a</label>Department of Radiology, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff2"><label>b</label>Department of Health Sciences Research, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff3"><label>c</label>Department of Psychiatry and Psychology, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff4"><label>d</label>Department of Internal Medicine, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff5"><label>e</label>Department of Information Technology, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff6"><label>f</label>Department of Neurology, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff><aff id="aff7"><label>g</label>Department of Medicine, School of Medicine and Public Health, <institution>University of Wisconsin and Geriatric Research</institution>, Education and Clinical Center (GRECC) William S. Middleton Memorial, Veterans&#x02019; Hospital, Madison, WI, <country>USA</country></aff><aff id="aff8"><label>h</label>Departments of Surgery, Physiology and Biomedical Engineering, <institution>Mayo Clinic</institution>, Rochester, MN, <country>USA</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tierney</surname><given-names>Mary</given-names></name><role>Handling Associate Editor</role></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Kejal Kantarci, MD, MS, Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel.: +1 507 284 9770; Fax: +1 507 284 9778; E-mail: <email>kantarci.kejal@mayo.edu</email>.</corresp></author-notes><pub-date date-type="preprint" publication-format="electronic"><day>7</day><month>5</month><year>2016</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>7</month><year>2016</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2016</year></pub-date><volume>53</volume><issue>2</issue><fpage>547</fpage><lpage>556</lpage><history><date date-type="accepted"><day>7</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>IOS Press and the authors. All rights reserved</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License</ext-link>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><bold>Background:</bold> It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer&#x02019;s disease (AD).</p><p><bold>Objective:</bold> To investigate the effects of hormone therapy on amyloid-&#x003b2; deposition in recently postmenopausal women.</p><p><bold>Methods:</bold> Participants within 5&#x02013;36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45&#x0200a;mg/day oral conjugated equine estrogens (CEE); 2) 50&#x003bc;g/day transdermal 17&#x003b2;-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200&#x0200a;mg/day) was given to active treatment groups for 12 days each month. <sup>11</sup>C Pittsburgh compound B (PiB) PET imaging was performed in 68 of the 118 participants at Mayo Clinic approximately seven years post randomization and three years after stopping randomized treatment. PiB Standard unit value ratio (SUVR) was calculated.</p><p><bold>Results:</bold> Women (age&#x0200a;=&#x0200a;52&#x02013;65) randomized to transdermal 17&#x003b2;-estradiol (<italic>n</italic>&#x0200a;=&#x0200a;21) had lower PiB SUVR compared to placebo (<italic>n</italic>&#x0200a;=&#x0200a;30) after adjusting for age [odds ratio (95% CI)&#x0200a;=&#x0200a;0.31(0.11&#x02013;0.83)]. In the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers, transdermal 17&#x003b2;-estradiol treated women (<italic>n</italic>&#x0200a;=&#x0200a;10) had lower PiB SUVR compared to either placebo (<italic>n</italic>&#x0200a;=&#x0200a;5) [odds ratio (95% CI)&#x0200a;=&#x0200a;0.04(0.004&#x02013;0.44)], or the oral CEE treated group (<italic>n</italic>&#x0200a;=&#x0200a;3) [odds ratio (95% CI)&#x0200a;=&#x0200a;0.01(0.0006&#x02013;0.23)] after adjusting for age. Hormone therapy was not associated with PiB SUVR in the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers.</p><p><bold>Conclusion:</bold> In this pilot study, transdermal 17&#x003b2;-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-&#x003b2; deposition, particularly in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers. This finding may have important implications for the prevention of AD in postmenopausal women, and needs to be confirmed in a larger sample.</p></abstract><kwd-group><label>Keywords</label><kwd>Alzheimer&#x02019;s disease</kwd><kwd>amyloid-&#x003b2;</kwd><kwd>cognitive function</kwd><kwd>estrogen</kwd><kwd>hormone therapy</kwd><kwd>menopause</kwd><kwd>PET</kwd><kwd>prevention</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>INTRODUCTION</title><p>Hormone therapy consisting of conjugated equine estrogens (CEE) along with medroxyprogesterone acetate initiated in the late postmenopause stage (&#x02265; 65 years) increased the risk of dementia in the Women&#x02019;s Health Initiative Memory Study (WHIMS) [<xref rid="ref001" ref-type="bibr">1</xref>]. However, there is controversy on whether estrogen with or without progesterone can preserve neurological function and decrease the risk of dementia when administered early in menopause, i.e., during a &#x0201c;window of opportunity&#x0201d; phase [<xref rid="ref002" ref-type="bibr">2&#x02013;8</xref>]. Although determining the effects of hormone treatment shortly after menopause on the risk of dementia would require decades of follow-up, non-invasive imaging markers of Alzheimer&#x02019;s disease (AD) pathophysiology can potentially assess the efficacy of preventive interventions in the short term.</p><p>The Kronos Early Estrogen Prevention Study (KEEPS) was a multi-center, randomized, placebo-controlled, double-blinded trial of hormone treatment in recently menopausal women who were in good cardiovascular health. KEEPS tested the hypothesis that hormone therapies administered soon after the onset of menopause would slow progression of atherosclerosis; [<xref rid="ref009" ref-type="bibr">9</xref>] however, no effect was observed on several imaging markers of progression of atherosclerosis during the four year trial [<xref rid="ref010" ref-type="bibr">10</xref>], or cognitive function [<xref rid="ref011" ref-type="bibr">11</xref>]. Although estrogens, in particular, are thought to modify the risk of AD, estrogen effects on amyloid-&#x003b2; (A&#x003b2;) pathology have not been investigated in a hormone treatment trial. Examining data obtained at one KEEPS enrollment site, we report the effects of two forms of hormone therapy, oral CEE and transdermal 17&#x003b2; estradiol therapy on A&#x003b2; deposition measured by Pittsburgh compound-B (PiB) PET.</p></sec><sec id="sec0010"><title>METHODS</title><sec id="sec0015"><title>Participants</title><p>KEEPS (NCT00154180) was a multicenter, randomized, double blinded, placebo-controlled clinical trial in recently menopausal women (<italic>n</italic>&#x0200a;=&#x0200a;727) that was conducted between 2006 and 2011. Participants enrolled in KEEPS were between 42 to 59 years of age, within 5 to 36 months past their last menses, and were in good cardiovascular health and did not have a history of hysterectomy or oophorectomy [<xref rid="ref009" ref-type="bibr">9</xref>]. Estrogens were administered through two different routes: Oral or transdermal. Participants were randomized to either: 1) oral conjugated equine estrogen (CEE; Premarin, 0.45&#x0200a;mg/day); 2) transdermal 17&#x003b2;-estradiol (skin patch, Climara, 50&#x003bc;g/day); or 3) placebo pills and patch. Progesterone was given orally (Prometrium; micronized progesterone, 200&#x0200a;mg/day) for the first 12 days each month to both active treatment groups. Participants were treated for four years.</p><p>Neuroimaging for the current study was conducted from December 2012 through July 2014 and included the subsample of women who were enrolled in KEEPS at the Mayo Clinic, to investigate the effects of the KEEPS hormone treatments on A&#x003b2; deposition three years after the end of the trial. This study was approved by the Mayo Clinic Institutional Review Board and all subjects or appropriate surrogates provided informed consent for participation Exclusion criteria for the imaging studies were contraindications for safety and neurologic disorders such as brain tumors, multiple sclerosis, neurodevelopmental abnormalities, or treatments (e.g., systemic chemotherapy) that would affect the brain structure. Apolipoprotein E (<italic>APOE</italic>) genotyping was performed after randomization and clinical examinations were performed at the Mayo Clinic Specialized Center of Research on Sex Differences within three months of the imaging studies. The study was approved by the Institutional Review Board at Mayo Clinic and all participants gave informed consent.</p></sec><sec id="sec0020"><title>Neuropsychological assessment and cognitive function</title><p>A confirmatory factor analysis was used to assess the underlying structure of baseline cognitive data from the KEEPS cognitive and affective study (<italic>n</italic>&#x0200a;=&#x0200a;662), and to derive summary scores [<xref rid="ref012" ref-type="bibr">12</xref>]. Using standard criteria for model fit, the cognitive variables were summarized with a general domain representing global cognitive function at baseline.</p><p>A battery of neuropsychological tests three years after the end of the hormone therapy phase were administered within three weeks of the neuroimaging examinations in the Research Psychometrics Resource Laboratory at Mayo Clinic&#x02019;s Center for Translational Science Activities (CTSA) under the direction of a neuropsychologist (JP). Cognitive performance was investigated in four domains: 1) Learning &#x00026; Memory from the California Verbal Learning Test (CVLT), New York University (NYU) Paragraphs, and Benton Visual Retention Test; 2) Auditory Attention &#x00026; Working Memory from Wechsler Memory Scale-III Letter-Number Sequencing and Digit Span subtests; 3) Visual Attention &#x00026; Perceptual Speed from Trail Making Test part A, Color and Word trials of the Stroop test, and Wechsler Adult Intelligence Scale-III Digit Symbol Coding subtest; 4) Speeded Language &#x00026; Flexibility from phonemic (F, A, S) and category (animals, fruits, vegetables) verbal fluency, Trail Making Test part B, and Color-Word Interference trial of the Stroop.</p></sec><sec id="sec0025"><title>MRI and PET imaging</title><p>MRI studies were performed on a single 1.5T system, with an 8-channel phased-array coil (GE Healthcare). A 3D high resolution MPRAGE acquisition with TR/TE/TI&#x0200a;=&#x0200a;7/3/900&#x0200a;ms; flip angle 8 degrees; in plane resolution of 1.0&#x0200a;mm and a slice thickness of 1.2&#x0200a;mm was performed for anatomical segmentation and labeling of PiB PET scans.</p><p>PET images were acquired using a PET/CT scanner (DRX; GE Healthcare) operating in 3D mode. The participants were injected with 292&#x02013;729 MBq [<sup>11</sup>C]PIB. A CT image was obtained for attenuation correction. After a 40-min uptake period, a 20-min PiB scan was obtained. The PiB- PET acquisition consisted of four 5-min dynamic frames, acquired from 40 to 60&#x0200a;min after injection. Standard corrections were applied. The pixel size for PET images was 1.0&#x0200a;mm and the slice thickness was 3.3&#x0200a;mm.</p></sec><sec id="sec0030"><title>Analysis of PiB PET</title><p>PiB PET quantitative image analysis was performed using the fully automated image processing pipeline which has been described in detail elsewhere [<xref rid="ref013" ref-type="bibr">13</xref>]. Briefly, the method includes gray matter (GM) sharpening of PET images using MRI and partial volume correction of cerebrospinal fluid and tissue compartments using Statistical Parametric Mapping unified segmentation algorithm [<xref rid="ref014" ref-type="bibr">14</xref>]. PiB PET cortical ratio images were calculated by dividing each PiB PET GM voxel value by the median value in the cerebellar GM region in patient&#x02019;s MRI space. PiB retention was calculated by the PiB Standard unit value ratio (SUVR), with the median values of the PiB PET GM ratio from the bilateral parietal, posterior cingulate, precuneus, temporal, prefrontal, orbitofrontal, anterior cingulate GM regions in the in-house modified anatomical labeling atlas.</p></sec><sec id="sec0035"><title>Statistical analysis</title><p>Characteristics of participants were compared across the treatment and the placebo groups using Kruskal-Wallis tests or Fisher exact tests, as appropriate. We also compared the characteristics of the participants and non-participants. Cognitive test scores were compared across the treatment and the placebo groups using ANOVA and Tukey&#x02019;s honest significant differences test for the <italic>post-hoc</italic> comparisons with adjustments. Age was tested for association with PiB SUVR using Spearman correlations. We performed the comparisons of PiB SUVR values across treatment and placebo groups, adjusting for age, using proportional odds logistic regressions [<xref rid="ref015" ref-type="bibr">15</xref>]. This semiparametric model mitigates the effect of outliers while allowing for parametric effects of age and treatment, and simultaneously estimates the log (odds) of higher versus lower value of PiB SUVR, at all possible threshold values. Thus, we did not classify the participants into A&#x003b2;-positive and A&#x003b2;-negative categories based on PiB SUVR.</p></sec></sec><sec id="sec0040"><title>RESULTS</title><p>All women enrolled in KEEPS at the Mayo Clinic in Rochester, Minnesota (<italic>n</italic>&#x0200a;=&#x0200a;118) were considered for participation in the current study. Six participants were excluded due to neurological disorders or MRI contraindications, forty women declined to participate in both MRI and/or PET studies, and four participants were lost to follow-up. Of the 112 eligible KEEPS participants, 68 women (61%) with median age of 60 (range, 52&#x02013;65) participated in both the MRI and PET studies and were included in the analysis (<xref ref-type="fig" rid="jad-53-jad160258-g001">Fig.&#x000a0;1</xref>). Participants included in the analysis did not differ from those who did not participate in the neuroimaging study on age (<italic>p</italic>&#x0200a;=&#x0200a;0.09), education (<italic>p</italic>&#x0200a;=&#x0200a;0.42), smoking status (<italic>p</italic>&#x0200a;=&#x0200a;0.48), time past from menopause to randomization (<italic>p</italic>&#x0200a;=&#x0200a;0.55), or <italic>APOE</italic> status (<italic>p</italic>&#x0200a;=&#x0200a;0.47).</p><p>The time elapsed between last menses and randomization was on average ten months longer in the oral CEE (<italic>p</italic>&#x0200a;=&#x0200a;0.05) and five months longer in the transdermal 17&#x003b2;-estradiol group compared to placebo (<italic>p</italic>&#x0200a;=&#x0200a;0.04). The transdermal 17&#x003b2;-estradiol group had a higher proportion of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers (50%) than the oral CEE (18%; <italic>p</italic>&#x0200a;=&#x0200a;0.08) and the placebo groups (18%; <italic>p</italic>&#x0200a;=&#x0200a;0.03). All <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers had the <italic>&#x0025b;</italic>4/<italic>&#x0025b;</italic>3 genotype. Three women declined <italic>APOE</italic> genetic testing (<xref ref-type="table" rid="jad-53-jad160258-t001">Table&#x000a0;1</xref>). All participants were cognitively normal on clinical examination and neuropsychological testing. There were no correlations between neuropsychometric test scores and the PiB SUVR values in the entire group as well as in the oral CEE, transdermal 17&#x003b2;-estradiol and placebo groups separately (<italic>p</italic>&#x0200a;&#x0003e;&#x0200a;0.09). However, after adjusting for age, education, <italic>APOE</italic>
<italic>&#x0025b;</italic>4 status, and time from menopause to randomization, CVLT Total Score was lower in the oral CEE group compared to placebo on ANOVA and <italic>post hoc</italic> Tukey&#x02019;s Honest Significant differences test (<italic>p</italic>&#x0200a;=&#x0200a;0.03) (<xref ref-type="table" rid="jad-53-jad160258-t002">Table&#x000a0;2</xref>).</p><p>Because of a difference in the proportion of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers among treatment groups, and the potential impact of this variable on outcome, a stratified analysis in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers and non-carriers was conducted. There was a significant association of PiB SUVR with age in the whole group (<italic>r</italic>&#x0200a;=&#x0200a;0.37; <italic>p</italic>&#x0200a;=&#x0200a;0.002), in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers (<italic>r</italic>&#x0200a;=&#x0200a;0.48; <italic>p</italic>&#x0200a;=&#x0200a;0.046), and in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers (<italic>r</italic>&#x0200a;=&#x0200a;0.43; <italic>p</italic>&#x0200a;=&#x0200a;0.003). Therefore, all analyses were adjusted by age (<xref ref-type="fig" rid="jad-53-jad160258-g002">Fig.&#x000a0;2</xref>).</p><p>The distribution of PiB SUVR varied by treatment group and by <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carrier status (<xref ref-type="fig" rid="jad-53-jad160258-g003">Fig.&#x000a0;3</xref>). Participants who were treated with 17&#x003b2;-estradiol were were more likely to have lower PiB SUVR compared to placebo after adjusting for age [odds ratio (95% CI)&#x0200a;=&#x0200a;0.31 (0.11&#x02013;0.83)]. By use of the proportional odds model, this odds ratio applies to any possible cut-point for PiB SUVR. In the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers (<italic>n</italic>&#x0200a;=&#x0200a;18), transdermal 17&#x003b2;-estradiol treated participants were more likely to have lower PiB SUVR compared to placebo [odds ratio (95% CI)&#x0200a;=&#x0200a;0.04 (0.004&#x02013;0.44)], and compared to the oral CEE treated participants [odds ratio (95% CI)&#x0200a;=&#x0200a;0.01 (0.0006&#x02013;0.23)] after adjusting for age. Treatment with either oral CEE or transdermal 17&#x003b2;-estradiol was not associated with PiB SUVR in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers (<italic>n</italic>&#x0200a;=&#x0200a;47) (<xref ref-type="fig" rid="jad-53-jad160258-g004">Fig.&#x000a0;4</xref>).</p></sec><sec id="sec0045"><title>DISCUSSION</title><p>This study of recently menopausal women who participated in a randomized controlled hormone therapy trial showed that A&#x003b2; deposition measured by PiB retention on PET was lower in women who received transdermal 17&#x003b2;-estradiol for four years compared to placebo. In contrast, oral CEE was not associated with a lower level of PiB retention. Although the oral CEE group performed worse on verbal learning and memory compared to placebo, this finding should be interpreted with caution because of the small sample size and because no correlation was found between PiB retention and cognitive test scores. Stratified analysis by <italic>APOE</italic>
<italic>&#x0025b;</italic>4 genotype showed that the lower PiB retention in the transdermal 17&#x003b2;-estradiol group was present only in the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers. Hormone therapy was not associated with PiB retention in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers.</p><p>A precipitous decline in endogenous estrogens with menopause is thought to be a major driver of AD risk in women. Hence, hormone therapy with estrogens offers the possibility for preventing or delaying the onset of AD in aging women [<xref rid="ref006" ref-type="bibr">6, 8, 16, 17</xref>]. Observational studies suggest that estrogen treatment, when administered to recently menopausal women, protects from age-associated cognitive decline and dementia [<xref rid="ref005" ref-type="bibr">5, 17&#x02013;25</xref>]. KEEPS was a randomized, placebo- controlled hormone therapy trial designed to test for intervention during the period of rapid estrogen depletion in recently menopausal women. Thus, KEEPS is ideally positioned to investigate the effects of hormone therapy on prevention of AD-related pathology during this &#x0201c;window of opportunity&#x0201d;.</p><p>PiB retention on PET imaging is a quantitative measure of A&#x003b2; deposition [<xref rid="ref026" ref-type="bibr">26</xref>]. High A&#x003b2; deposition measured on PET imaging or via cerebrospinal fluid is considered to be the earliest biomarker change observed during the preclinical stages of AD [<xref rid="ref027" ref-type="bibr">27, 28</xref>]. Thus, PiB retention on PET is an appropriate biomarker to investigate whether hormone therapy influences A&#x003b2; deposition specifically during the early menopausal years when the effect of A&#x003b2; deposition on cognitive function is not yet manifested. We observed no differences in cognitive function among the 17&#x003b2;-estradiol and placebo groups. However, a randomized controlled trial of oral 17&#x003b2;-estradiol in older women (age: 61&#x02013;87) found less decline in short-delayed verbal recall compared to placebo [<xref rid="ref029" ref-type="bibr">29</xref>]. Hence, the effects of lower levels of A&#x003b2; deposition in the transdermal 17&#x003b2;-estradiol group on cognitive function may be apparent later in life.</p><p>Carriers of the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 allele are at an increased risk of AD dementia; moreover the risk may be higher in women than in men [<xref rid="ref030" ref-type="bibr">30, 31</xref>]. <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers have increased A&#x003b2; deposition at an earlier age than <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers, and this difference is more pronounced in women than in men [<xref rid="ref032" ref-type="bibr">32, 33</xref>]. Thus, women who are <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers are at a higher risk for AD-related pathology and may benefit most from preventive interventions at an early age. In the current study, we found that postmenopausal transdermal 17&#x003b2;-estradiol is associated with lower levels of A&#x003b2; deposition compared to placebo particularly among women who are <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers. We interpret this finding in two possible ways.</p><p>The first possible interpretation is that <italic>APOE</italic> status modifies the effect of transdermal 17&#x003b2;-estradiol on A&#x003b2; deposition as a pharmacogenetic effect. This interpretation is consistent with observations where <italic>APOE</italic> also modulates the effect of transdermal 17&#x003b2;-estradiol therapy on A&#x003b2; deposition in live mice, [<xref rid="ref034" ref-type="bibr">34</xref>] and in cultured adult mouse cortical neurons [<xref rid="ref035" ref-type="bibr">35</xref>]. <italic>APOE</italic>
<italic>&#x0025b;</italic>4 status appears to modify the effects of hormone therapy on cognitive function and dementia also in humans; however, the findings are conflicting [<xref rid="ref036" ref-type="bibr">36&#x02013;38</xref>]. In one observational study, <italic>APOE</italic>
<italic>&#x0025b;</italic>4 positive women opting to use hormone therapy had lower risk of dementia, however, the forms of hormone therapy were not specified [<xref rid="ref036" ref-type="bibr">36</xref>]. On the contrary, <italic>APOE</italic>
<italic>&#x0025b;</italic>4 positive women had more cognitive decline than <italic>APOE</italic>
<italic>&#x0025b;</italic>4 negative women if they used hormone therapy (primarily with oral CEE) in two other observational studies [<xref rid="ref037" ref-type="bibr">37, 38</xref>]. Similarly, we did not find an association of oral CEE therapy with A&#x003b2; deposition compared to placebo. In fact, <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers treated with oral CEE showed higher levels of A&#x003b2; deposition than <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers treated with transdermal 17&#x003b2;-estradiol. However because of the low number of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers in the CEE group, this finding needs to be interpreted with caution. In WHIMS, oral CEE therapy along with medroxyprogesterone acetate, initiated in older women (age&#x02265;65) increased the risk of dementia and brain atrophy, which persisted into older ages [<xref rid="ref001" ref-type="bibr">1, 2, 39, 40</xref>]; however, the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 status of women in WHIMS was not reported. Because CEE increases serum levels of estrone and of sulfonated conjugates more than transdermal 17&#x003b2;-estradiol, it is possible that the various circulating estrogens would have different efficacy in binding and activation of estrogen receptor mediated events such as the deposition of A&#x003b2; [<xref rid="ref041" ref-type="bibr">41</xref>]. Further work is needed to understand how higher doses of oral CEE (e.g., 0.625&#x0200a;mg/day as used in the Women&#x02019;s Health Initiative), may increase the circulating levels of 17&#x003b2;-estradiol to those comparable to the transdermal 17&#x003b2;- estradiol treatment group.</p><p>A second possible interpretation of the finding is that the <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers included in our study were too young to show hormone therapy effects on A&#x003b2; deposition. Participants recruited to the PET study three years after KEEPS were at a median age of 60 with a range of 52 to 65. In the population-based Mayo Clinic Study of Aging, the estimated age at which 10% of the population had high levels of A&#x003b2; deposition was 57 years for <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers and 64 years for <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers [<xref rid="ref042" ref-type="bibr">42</xref>]. Thus, it may be too early to detect transdermal 17&#x003b2;-estradiol effects on A&#x003b2; deposition in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 non-carriers in the current study. Further follow-up of the cohort is planned to determine whether transdermal 17&#x003b2;-estradiol therapy in recently menopausal women is associated with A&#x003b2; deposition in older age.</p><p>This study was conducted at a single KEEPS site; therefore, the sample size is limited. Our findings need to be confirmed in a larger sample perhaps by including all KEEPS sites. The participation rate (with the exclusions) for this multimodality imaging study is comparable to the imaging participation rate observed in other hormone therapy trials such as the WHIMS-MRI study [<xref rid="ref040" ref-type="bibr">40</xref>]. A higher proportion of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers in the transdermal 17&#x003b2;-estradiol group is not surprising given the relatively small number of women included this pilot study. Randomization does not guarantee a balanced allocation across treatment groups when the numbers are small. Lower A&#x003b2; deposition in the transdermal 17&#x003b2;-estradiol group compared to placebo cannot be explained by the higher proportion of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers in the transdermal 17&#x003b2;-estradiol group than the placebo. In fact, the opposite would be expected, because A&#x003b2; deposition should be highest in a group with a higher proportion of <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers. Although the study cohort was randomized to hormone therapies and placebo 7 years ago, cardiovascular risk factors and biomarkers remained comparable in the oral CEE, transdermal 17&#x003b2;-estradiol and placebo groups at 84 months (7 years) post-randomization. KEEPS was designed to include women who were in good cardiovascular and neurological health, therefore generalization of our findings to a broader population may be limited. Yet, in a homogenously healthy cohort of women, the potential effects of hormone therapy on A&#x003b2; deposition are not confounded by vascular disease and perhaps define a population who might benefit from the use of transdermal 17&#x003b2;-estradiol.</p><p>The consequences of A&#x003b2; deposition during early menopausal years are not fully understood, and effectiveness of early menopausal hormone therapy in preventing AD-related pathology in the long-term remains unclear. However, reducing A&#x003b2; deposition through A&#x003b2;-modifying therapies is a widely accepted strategy for preventing AD, and clinical trials are underway in cognitively normal individuals with high PiB retention, [<xref rid="ref043" ref-type="bibr">43</xref>] and in <italic>APOE</italic>
<italic>&#x0025b;</italic>4 carriers [<xref rid="ref044" ref-type="bibr">44</xref>]. The association of transdermal 17&#x003b2;-estradiol therapy in recently menopausal women with lower A&#x003b2; deposition has the potential to change the concepts for preventive interventions that drive the field, and may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute, NIH (NS66147, AG029624 and AG44170). The authors thank Ms. Kim Jensen for consenting and scheduling of the participants. The authors do not have any conflicts of interest related to the submitted work. The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p><p>Authors&#x02019; disclosures available online (<ext-link ext-link-type="uri" xlink:href="http://j-alz.com/manuscript-disclosures/16-0258r1">http://j-alz.com/manuscript-disclosures/16-0258r1</ext-link>).</p></ack><ref-list><title>REFERENCES</title><ref id="ref001"><label>[1]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Shumaker</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Legault</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rapp</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Thal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Fillit</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Stefanick</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Hendrix</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Masaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Coker</surname>
<given-names>LH</given-names>
</string-name> (<year>2004</year>) <article-title>Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women&#x02019;s Health Initiative Memory Study</article-title>. <source>JAMA</source>
<volume>291</volume>, <fpage>2947</fpage>&#x02013;<lpage>2958</lpage>.<pub-id pub-id-type="pmid">15213206</pub-id></mixed-citation></ref><ref id="ref002"><label>[2]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Espeland</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Shumaker</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Leng</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Manson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>LeBlanc</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Vaughan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rapp</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Goveas</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Wactawski-Wende</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stefanick</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Resnick</surname>
<given-names>SM</given-names>
</string-name> (<year>2013</year>) <article-title>Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years</article-title>. <source>JAMA Intern Med</source>
<volume>173</volume>, <fpage>1429</fpage>&#x02013;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">23797469</pub-id></mixed-citation></ref><ref id="ref003"><label>[3]</label><mixed-citation publication-type="journal">
<string-name>
<surname>LeBlanc</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Janowsky</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>HD</given-names>
</string-name> (<year>2001</year>) <article-title>Hormone replacement therapy and cognition: Systematic review and meta-analysis</article-title>. <source>JAMA</source>
<volume>285</volume>, <fpage>1489</fpage>&#x02013;<lpage>1499</lpage>.<pub-id pub-id-type="pmid">11255426</pub-id></mixed-citation></ref><ref id="ref004"><label>[4]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Grossardt</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Shuster</surname>
<given-names>LT</given-names>
</string-name> (<year>2011</year>) <article-title>Oophorectomy, menopause, estrogen treatment, and cognitive aging: Clinical evidence for a window of opportunity</article-title>. <source>Brain Res</source>
<volume>1379</volume>, <fpage>188</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">20965156</pub-id></mixed-citation></ref><ref id="ref005"><label>[5]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sherwin</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>JF</given-names>
</string-name> (<year>2008</year>) <article-title>Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: A critical review</article-title>. <source>Front Neuroendocrinol</source>
<volume>29</volume>, <fpage>88</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">17980408</pub-id></mixed-citation></ref><ref id="ref006"><label>[6]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Waring</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>O&#x02019;Brien</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Tangalos</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Kokmen</surname>
<given-names>E</given-names>
</string-name> (<year>1999</year>) <article-title>Postmenopausal estrogen replacement therapy and risk of AD: A population-based study</article-title>. <source>Neurology</source>
<volume>52</volume>, <fpage>965</fpage>&#x02013;<lpage>970</lpage>.<pub-id pub-id-type="pmid">10102413</pub-id></mixed-citation></ref><ref id="ref007"><label>[7]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sawaya</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lieberburg</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Grady</surname>
<given-names>D</given-names>
</string-name> (<year>1998</year>) <article-title>Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia</article-title>. <source>JAMA</source>
<volume>279</volume>, <fpage>688</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">9496988</pub-id></mixed-citation></ref><ref id="ref008"><label>[8]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zandi</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Plassman</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Welsh-Bohmer</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Steffens</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Breitner</surname>
<given-names>JC</given-names>
</string-name>, <collab>Cache County Memory Study I</collab> (<year>2002</year>) <article-title>Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study</article-title>. <source>JAMA</source>
<volume>288</volume>, <fpage>2123</fpage>&#x02013;<lpage>2129</lpage>.<pub-id pub-id-type="pmid">12413371</pub-id></mixed-citation></ref><ref id="ref009"><label>[9]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Harman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Cedars</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lobo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Manson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Merriam</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Naftolin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Santoro</surname>
<given-names>N</given-names>
</string-name> (<year>2005</year>) <article-title>KEEPS: The Kronos Early Estrogen Prevention Study</article-title>. <source>Climacteric</source>
<volume>8</volume>, <fpage>3</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15804727</pub-id></mixed-citation></ref><ref id="ref010"><label>[10]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Harman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Naftolin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Budoff</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cedars</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Hopkins</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Manson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Merriam</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Neal-Perry</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Santoro</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Vittinghoff</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hodis</surname>
<given-names>HN</given-names>
</string-name> (<year>2014</year>) <article-title>Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial</article-title>. <source>Ann Intern Med</source>
<volume>161</volume>, <fpage>249</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">25069991</pub-id></mixed-citation></ref><ref id="ref011"><label>[11]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gleason</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Dowling</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Wharton</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Manson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Atwood</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Cedars</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Merriam</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Neal-Perry</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Santoro</surname>
<given-names>NF</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Budoff</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hodis</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Naftolin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Harman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Asthana</surname>
<given-names>S</given-names>
</string-name> (<year>2015</year>) <article-title>Effects of hormone therapy on cognition and mood in recently postmenopausal women: Findings from the randomized, controlled KEEPS-Cognitive and Affective Study</article-title>. <source>PLoS Med</source>
<volume>12</volume>, <fpage>e1001833</fpage>; <comment>discussion e1001833</comment>.<pub-id pub-id-type="pmid">26035291</pub-id></mixed-citation></ref><ref id="ref012"><label>[12]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dowling</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Gleason</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Manson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Hodis</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Neal-Perry</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Santoro</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Cedars</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lobo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Merriam</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Wharton</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Naftolin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Harman</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Asthana</surname>
<given-names>S</given-names>
</string-name> (<year>2013</year>) <article-title>Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e68741</fpage>.<pub-id pub-id-type="pmid">23874743</pub-id></mixed-citation></ref><ref id="ref013"><label>[13]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Lowe</surname>
<given-names>VJ</given-names>
</string-name>, <string-name>
<surname>Senjem</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Shiung</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Klunk</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Mathis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</string-name> (<year>2008</year>) <article-title>11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x02019;s disease and amnestic mild cognitive impairment</article-title>. <source>Brain</source>
<volume>131</volume>, <fpage>665</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">18263627</pub-id></mixed-citation></ref><ref id="ref014"><label>[14]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ashburner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Friston</surname>
<given-names>KJ</given-names>
</string-name> (<year>2005</year>) <article-title>Unified segmentation</article-title>. <source>Neuroimage</source>
<volume>26</volume>, <fpage>839</fpage>&#x02013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">15955494</pub-id></mixed-citation></ref><ref id="ref015"><label>[15]</label><mixed-citation publication-type="journal">
<string-name>
<surname>McCullagh</surname>
<given-names>P</given-names>
</string-name> (<year>1980</year>) <article-title>Regression models for ordinal data (with discussion)</article-title>. <source>J R Stat Soc Series B Stat Methodol</source>
<volume>42</volume>, <fpage>109</fpage>&#x02013;<lpage>142</lpage>.</mixed-citation></ref><ref id="ref016"><label>[16]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Paganini-Hill</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>
<given-names>VW</given-names>
</string-name> (<year>1994</year>) <article-title>Estrogen deficiency and risk of Alzheimer&#x02019;s disease in women</article-title>. <source>Am J Epidemiol</source>
<volume>140</volume>, <fpage>256</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="pmid">8030628</pub-id></mixed-citation></ref><ref id="ref017"><label>[17]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Grossardt</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Shuster</surname>
<given-names>LT</given-names>
</string-name> (<year>2014</year>) <article-title>Oophorectomy, estrogen, and dementia: A 2014 update</article-title>. <source>Mol Cell Endocrinol</source>
<volume>389</volume>, <fpage>7</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">24508665</pub-id></mixed-citation></ref><ref id="ref018"><label>[18]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Resnick</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>
<given-names>VW</given-names>
</string-name> (<year>2002</year>) <article-title>Hormone therapy and risk of Alzheimer disease: A critical time</article-title>. <source>JAMA</source>
<volume>288</volume>, <fpage>2170</fpage>&#x02013;<lpage>2172</lpage>.<pub-id pub-id-type="pmid">12413378</pub-id></mixed-citation></ref><ref id="ref019"><label>[19]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mack</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Cadenas</surname>
<given-names>E</given-names>
</string-name> (<year>2015</year>) <article-title>Perimenopause as a neurological transition state</article-title>. <source>Nat Rev Endocrinol</source>
<volume>11</volume>, <fpage>393</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">26007613</pub-id></mixed-citation></ref><ref id="ref020"><label>[20]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</string-name> (<year>2009</year>) <article-title>Estrogen-induced plasticity from cells to circuits: Predictions for cognitive function</article-title>. <source>Trends Pharmacol Sci</source>
<volume>30</volume>, <fpage>212</fpage>&#x02013;<lpage>222</lpage>.<pub-id pub-id-type="pmid">19299024</pub-id></mixed-citation></ref><ref id="ref021"><label>[21]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Henderson</surname>
<given-names>VW</given-names>
</string-name>, <string-name>
<surname>Benke</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Cupples</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Farrer</surname>
<given-names>LA</given-names>
</string-name> (<year>2005</year>) <article-title>Postmenopausal hormone therapy and Alzheimer&#x02019;s disease risk: Interaction with age</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<volume>76</volume>, <fpage>103</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">15608005</pub-id></mixed-citation></ref><ref id="ref022"><label>[22]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Maki</surname>
<given-names>PM</given-names>
</string-name> (<year>2013</year>) <article-title>Critical window hypothesis of hormone therapy and cognition: A scientific update on clinical studies</article-title>. <source>Menopause</source>
<volume>20</volume>, <fpage>695</fpage>&#x02013;<lpage>709</lpage>.<pub-id pub-id-type="pmid">23715379</pub-id></mixed-citation></ref><ref id="ref023"><label>[23]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Shao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Breitner</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Whitmer</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hayden</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wengreen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Corcoran</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tschanz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Norton</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Munger</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Welsh-Bohmer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zandi</surname>
<given-names>PP</given-names>
</string-name> (<year>2012</year>) <article-title>Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study</article-title>. <source>Neurology</source>
<volume>79</volume>, <fpage>1846</fpage>&#x02013;<lpage>1852</lpage>.<pub-id pub-id-type="pmid">23100399</pub-id></mixed-citation></ref><ref id="ref024"><label>[24]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Whitmer</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Quesenberry</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name> (<year>2011</year>) <article-title>Timing of hormone therapy and dementia: The critical window theory revisited</article-title>. <source>Ann Neurol</source>
<volume>69</volume>, <fpage>163</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">21280086</pub-id></mixed-citation></ref><ref id="ref025"><label>[25]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</string-name> (<year>2011</year>) <article-title>17beta-Estradiol regulates insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: Relevance to Alzheimer&#x02019;s prevention</article-title>. <source>Neurobiol Aging</source>
<volume>32</volume>, <fpage>1949</fpage>&#x02013;<lpage>1963</lpage>.<pub-id pub-id-type="pmid">20053478</pub-id></mixed-citation></ref><ref id="ref026"><label>[26]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ikonomovic</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Klunk</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Abrahamson</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Mathis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Tsopelas</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Lopresti</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Ziolko</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Paljug</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Debnath</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Hope</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Isanski</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</string-name> (<year>2008</year>) <article-title>Post-mortem correlates of <italic>in vivo</italic> PiB-PET amyloid imaging in a typical case of Alzheimer&#x02019;s disease</article-title>. <source>Brain</source>
<volume>131</volume>, <fpage>1630</fpage>&#x02013;<lpage>1645</lpage>.<pub-id pub-id-type="pmid">18339640</pub-id></mixed-citation></ref><ref id="ref027"><label>[27]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sperling</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Aisen</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Beckett</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Craft</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fagan</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Kaye</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Montine</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Reiman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Siemers</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Carrillo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Thies</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Morrison-Bogorad</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wagster</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Phelps</surname>
<given-names>CH</given-names>
</string-name> (<year>2011</year>) <article-title>Toward defining the preclinical stages of Alzheimer&#x02019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source>
<volume>7</volume>, <fpage>280</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">21514248</pub-id></mixed-citation></ref><ref id="ref028"><label>[28]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Jagust</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Aisen</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Weiner</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>JQ</given-names>
</string-name> (<year>2010</year>) <article-title>Hypothetical model of dynamic biomarkers of the Alzheimer&#x02019;s pathological cascade</article-title>. <source>Lancet Neurol</source>
<volume>9</volume>, <fpage>119</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">20083042</pub-id></mixed-citation></ref><ref id="ref029"><label>[29]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tierney</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Moineddin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Greenblatt</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Snow</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Iazzetta</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hyslop</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>MacLusky</surname>
<given-names>NJ</given-names>
</string-name> (<year>2009</year>) <article-title>A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women</article-title>. <source>Psychoneuroendocrinology</source>
<volume>34</volume>, <fpage>1065</fpage>&#x02013;<lpage>1074</lpage>.<pub-id pub-id-type="pmid">19297102</pub-id></mixed-citation></ref><ref id="ref030"><label>[30]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Payami</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zareparsi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Montee</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Sexton</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Kaye</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Wijsman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Heston</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Litt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schellenberg</surname>
<given-names>GD</given-names>
</string-name> (<year>1996</year>) <article-title>Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: A possible clue to the higher incidence of Alzheimer disease in women</article-title>. <source>Am J Hum Genet</source>
<volume>58</volume>, <fpage>803</fpage>&#x02013;<lpage>811</lpage>.<pub-id pub-id-type="pmid">8644745</pub-id></mixed-citation></ref><ref id="ref031"><label>[31]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Mielke</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Vemuri</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>VM</given-names>
</string-name> (<year>2014</year>) <article-title>Sex and gender differences in the causes of dementia: A narrative review</article-title>. <source>Maturitas</source>
<volume>79</volume>, <fpage>196</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">24954700</pub-id></mixed-citation></ref><ref id="ref032"><label>[32]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Altmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>
<given-names>VW</given-names>
</string-name>, <string-name>
<surname>Greicius</surname>
<given-names>MD</given-names>
</string-name> (<year>2014</year>) <article-title>Sex modifies the APOE-related risk of developing Alzheimer disease</article-title>. <source>Ann Neurol</source>
<volume>75</volume>, <fpage>563</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">24623176</pub-id></mixed-citation></ref><ref id="ref033"><label>[33]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Corder</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Ghebremedhin</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Thal</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Ohm</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>H</given-names>
</string-name> (<year>2004</year>) <article-title>The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: Modification by age, sex, and APOE polymorphism</article-title>. <source>Ann N Y Acad Sci</source>
<volume>1019</volume>, <fpage>24</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">15246987</pub-id></mixed-citation></ref><ref id="ref034"><label>[34]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kunzler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Youmans</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ladu</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Tai</surname>
<given-names>LM</given-names>
</string-name> (<year>2014</year>) <article-title>APOE modulates the effect of estrogen therapy on Abeta accumulation EFAD-Tg mice</article-title>. <source>Neurosci Lett</source>
<volume>560</volume>, <fpage>131</fpage>&#x02013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">24368217</pub-id></mixed-citation></ref><ref id="ref035"><label>[35]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Nathan</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Barsukova</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>McAsey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Struble</surname>
<given-names>RG</given-names>
</string-name> (<year>2004</year>) <article-title>Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons</article-title>. <source>Endocrinology</source>
<volume>145</volume>, <fpage>3065</fpage>&#x02013;<lpage>3073</lpage>.<pub-id pub-id-type="pmid">15033916</pub-id></mixed-citation></ref><ref id="ref036"><label>[36]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ryan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Carriere</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Scali</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dartigues</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Tzourio</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Poncet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ritchie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ancelin</surname>
<given-names>ML</given-names>
</string-name> (<year>2009</year>) <article-title>Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study</article-title>. <source>Neurology</source>
<volume>73</volume>, <fpage>1729</fpage>&#x02013;<lpage>1737</lpage>.<pub-id pub-id-type="pmid">19933973</pub-id></mixed-citation></ref><ref id="ref037"><label>[37]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kang</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Grodstein</surname>
<given-names>F</given-names>
</string-name> (<year>2012</year>) <article-title>Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline</article-title>. <source>Neurobiol Aging</source>
<volume>33</volume>, <fpage>1129</fpage>&#x02013;<lpage>1137</lpage>.<pub-id pub-id-type="pmid">21122949</pub-id></mixed-citation></ref><ref id="ref038"><label>[38]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Byers</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tangen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>L</given-names>
</string-name> (<year>2000</year>) <article-title>Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction</article-title>. <source>Neurology</source>
<volume>54</volume>, <fpage>1949</fpage>&#x02013;<lpage>1954</lpage>.<pub-id pub-id-type="pmid">10822435</pub-id></mixed-citation></ref><ref id="ref039"><label>[39]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Espeland</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Tindle</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Bushnell</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Jaramillo</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Margolis</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Mysiw</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Maldjian</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Melhem</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Resnick</surname>
<given-names>SM</given-names>
</string-name> (<year>2009</year>) <article-title>Brain volumes, cognitive impairment, and conjugated equine estrogens</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<volume>64</volume>, <fpage>1243</fpage>&#x02013;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">19729392</pub-id></mixed-citation></ref><ref id="ref040"><label>[40]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Coker</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Hogan</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Bryan</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Margolis</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Bettermann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Lao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stefanick</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Shumaker</surname>
<given-names>SA</given-names>
</string-name> (<year>2009</year>) <article-title>Postmenopausal hormone therapy and subclinical cerebrovascular disease: The WHIMS-MRI Study</article-title>. <source>Neurology</source>
<volume>72</volume>, <fpage>125</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">19139363</pub-id></mixed-citation></ref><ref id="ref041"><label>[41]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jaffe</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Toran-Allerand</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Greengard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gandy</surname>
<given-names>SE</given-names>
</string-name> (<year>1994</year>) <article-title>Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein</article-title>. <source>J Biol Chem</source>
<volume>269</volume>, <fpage>13065</fpage>&#x02013;<lpage>13068</lpage>.<pub-id pub-id-type="pmid">8175728</pub-id></mixed-citation></ref><ref id="ref042"><label>[42]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Wiste</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Weigand</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Vemuri</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mielke</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Lowe</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Senjem</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Gunter</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Machulda</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Gregg</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Pankratz</surname>
<given-names>VS</given-names>
</string-name>, <string-name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</string-name> (<year>2015</year>) <article-title>Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span</article-title>. <source>JAMA Neurol</source>
<volume>72</volume>, <fpage>511</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">25775353</pub-id></mixed-citation></ref><ref id="ref043"><label>[43]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sperling</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Rentz</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Karlawish</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Donohue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Salmon</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Aisen</surname>
<given-names>P</given-names>
</string-name> (<year>2014</year>) <article-title>The A4 study: Stopping AD before symptoms begin?</article-title>. <source>Sci Transl Med</source>
<volume>6</volume>, <comment>228fs213</comment>.</mixed-citation></ref><ref id="ref044"><label>[44]</label><mixed-citation publication-type="journal">
<string-name>
<surname>Reiman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Langbaum</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Fleisher</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Caselli</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ayutyanont</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Quiroz</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Kosik</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Lopera</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tariot</surname>
<given-names>PN</given-names>
</string-name> (<year>2011</year>) <article-title>Alzheimer&#x02019;s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments</article-title>. <source>J Alzheimers Dis</source>
<volume>26</volume>(<issue>Suppl 3</issue>), <fpage>321</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">21971471</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="jad-53-jad160258-g001" orientation="portrait" position="float"><label>Fig.1</label><caption><p>Participation flowchart: <sup>*</sup> There were six exclusions: One woman with an MRI incompatible implant (oral CEE group); one woman with posterior fossa developmental abnormality and hydrocephalus, one woman who developed breast cancer and underwent systemic chemotherapy (transdermal 17&#x003b2;-estradiol group); two women with multiple sclerosis and one woman with a benign brain tumor (placebo group).</p></caption><graphic xlink:href="jad-53-jad160258-g001"/></fig><fig id="jad-53-jad160258-g002" orientation="portrait" position="float"><label>Fig.2</label><caption><p>Associations of PiB SUVR with age in the whole group of participants, in APOE <italic>&#x0025b;</italic>4 carriers, and in APOE <italic>&#x0025b;</italic>4 non-carriers.</p></caption><graphic xlink:href="jad-53-jad160258-g002"/></fig><fig id="jad-53-jad160258-g003" orientation="portrait" position="float"><label>Fig.3</label><caption><p>PiB SUVR in the oral CEE, transdermal 17&#x003b2;-estradiol, and the placebo groups in the whole group of participants, in APOE <italic>&#x0025b;</italic>4 carriers, and in APOE <italic>&#x0025b;</italic>4 non-carriers.</p></caption><graphic xlink:href="jad-53-jad160258-g003"/></fig><fig id="jad-53-jad160258-g004" orientation="portrait" position="float"><label>Fig.4</label><caption><p>Odds ratios for PiB SUVR from proportional odds logistic regression models and 95% Wald confidence limits comparing PiB SUVR in oral CEE, transdermal 17&#x003b2;-estradiol, and the placebo groups in the whole group of participants, in APOE <italic>&#x0025b;</italic>4 carriers, and in APOE <italic>&#x0025b;</italic>4 non-carriers after adjusting for age. The odds ratio axis is logarithmic to accommodate the entire range of 95% Wald confidence limits.</p></caption><graphic xlink:href="jad-53-jad160258-g004"/></fig><table-wrap id="jad-53-jad160258-t001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the participants by treatment status</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Characteristic<sup>a</sup></td><td rowspan="1" colspan="1">CEE (<italic>N</italic>&#x0200a;=&#x0200a;17)</td><td rowspan="1" colspan="1">17&#x003b2;-Estradiol (<italic>N</italic>&#x0200a;=&#x0200a;21)</td><td rowspan="1" colspan="1">Placebo (<italic>N</italic>&#x0200a;=&#x0200a;30)</td><td rowspan="1" colspan="1">p<sup>b</sup></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, year at baseline</td><td rowspan="1" colspan="1">54 (46, 58)</td><td rowspan="1" colspan="1">53 (45, 58)</td><td rowspan="1" colspan="1">53 (45, 58)</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Age, year at the PET scan</td><td rowspan="1" colspan="1">61 (53, 65)</td><td rowspan="1" colspan="1">60 (52, 65)</td><td rowspan="1" colspan="1">60 (52, 65)</td><td rowspan="1" colspan="1">0.48</td></tr><tr><td rowspan="1" colspan="1">Education, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.65</td></tr><tr><td rowspan="1" colspan="1">&#x02003; High school or less</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">1 (5)</td><td rowspan="1" colspan="1">3 (10)</td></tr><tr><td rowspan="1" colspan="1">&#x02003; Some college / College graduate</td><td rowspan="1" colspan="1">12 (80)</td><td rowspan="1" colspan="1">12 (63)</td><td rowspan="1" colspan="1">17 (57)</td></tr><tr><td rowspan="1" colspan="1">&#x02003; Some graduate / Graduate</td><td rowspan="1" colspan="1">2 (13)</td><td rowspan="1" colspan="1">6 (32)</td><td rowspan="1" colspan="1">10 (33)</td></tr><tr><td rowspan="1" colspan="1">Smoking status, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">&#x02003; Non-smoker</td><td rowspan="1" colspan="1">10 (71)</td><td rowspan="1" colspan="1">8 (50)</td><td rowspan="1" colspan="1">20 (71)</td></tr><tr><td rowspan="1" colspan="1">&#x02003; Smoker</td><td rowspan="1" colspan="1">4 (29)</td><td rowspan="1" colspan="1">8 (50)</td><td rowspan="1" colspan="1">8 (29)</td></tr><tr><td rowspan="1" colspan="1">Time past menopause to randomization (months)</td><td rowspan="1" colspan="1">23 (7, 35)<sup>*</sup></td><td rowspan="1" colspan="1">18 (7, 36)<sup>*</sup></td><td rowspan="1" colspan="1">13 (5, 36)</td><td rowspan="1" colspan="1">0.045</td></tr><tr><td rowspan="1" colspan="1">APOE carrier, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">3 (18)</td><td rowspan="1" colspan="1">10 (50)<sup>*</sup></td><td rowspan="1" colspan="1">5 (18)</td><td rowspan="1" colspan="1">0.04</td></tr><tr><td rowspan="1" colspan="1">Migraines, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">1 (6)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">3 (10)</td><td rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1">Global Cognition at baseline</td><td rowspan="1" colspan="1">&#x02013;0.12 (&#x02013;1.79, 1.67)</td><td rowspan="1" colspan="1">0.38 (&#x02013;1.84, 1.15)</td><td rowspan="1" colspan="1">0.08 (&#x02013;1.06, 1.83)</td><td rowspan="1" colspan="1">0.23</td></tr><tr><td rowspan="1" colspan="1">Mean systolic blood pressure, mm Hg at baseline</td><td rowspan="1" colspan="1">121 (96, 146)</td><td rowspan="1" colspan="1">114 (88, 149)</td><td rowspan="1" colspan="1">124 (96, 152)</td><td rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="1" colspan="1">Mean systolic blood pressure, mm Hg at the PET scan</td><td rowspan="1" colspan="1">88 (77, 116)</td><td rowspan="1" colspan="1">84 (68, 104)</td><td rowspan="1" colspan="1">93 (68, 116)</td><td rowspan="1" colspan="1">0.32</td></tr><tr><td rowspan="1" colspan="1">Mean diastolic blood pressure, mm Hg at baseline</td><td rowspan="1" colspan="1">78 (66, 91)</td><td rowspan="1" colspan="1">72 (60, 87)</td><td rowspan="1" colspan="1">76 (60, 88)</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">Mean diastolic blood pressure, mm Hg at the PET scan</td><td rowspan="1" colspan="1">123 (95, 156)</td><td rowspan="1" colspan="1">128 (94, 149)</td><td rowspan="1" colspan="1">128 (97, 149)</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup> at baseline</td><td rowspan="1" colspan="1">26 (20, 36)</td><td rowspan="1" colspan="1">25 (18, 34)</td><td rowspan="1" colspan="1">26 (19, 33)</td><td rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup> at the PET scan</td><td rowspan="1" colspan="1">77 (62, 96)</td><td rowspan="1" colspan="1">76 (60, 88)</td><td rowspan="1" colspan="1">79 (60, 93)</td><td rowspan="1" colspan="1">0.81</td></tr><tr><td rowspan="1" colspan="1">Coronary arterial calcification present, <italic>n</italic> (%) at baseline</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (10)</td><td rowspan="1" colspan="1">4 (13)</td><td rowspan="1" colspan="1">0.41</td></tr><tr><td rowspan="1" colspan="1">Coronary arterial calcification present, <italic>n</italic> (%) at the PET scan</td><td rowspan="1" colspan="1">1 (6)</td><td rowspan="1" colspan="1">3 (14)</td><td rowspan="1" colspan="1">4 (13)</td><td rowspan="1" colspan="1">0.79</td></tr><tr><td rowspan="1" colspan="1">Carotid intima-media thickness at baseline</td><td rowspan="1" colspan="1">0.69 (0.55, 0.80)</td><td rowspan="1" colspan="1">0.64 (0.56, 0.85)</td><td rowspan="1" colspan="1">0.66 (0.57, 0.87)</td><td rowspan="1" colspan="1">0.91</td></tr><tr><td rowspan="1" colspan="1">Carotid intima-media thickness at the PET scan</td><td rowspan="1" colspan="1">0.73 (0.61, 0.88)</td><td rowspan="1" colspan="1">0.74 (0.56, 0.99)</td><td rowspan="1" colspan="1">0.73 (0.58, 1.01)</td><td rowspan="1" colspan="1">0.73</td></tr><tr><td rowspan="1" colspan="1">Low-density lipoprotein, mg/dL at baseline</td><td rowspan="1" colspan="1">121 (79, 163)</td><td rowspan="1" colspan="1">117 (64, 172)</td><td rowspan="1" colspan="1">114 (53, 178)</td><td rowspan="1" colspan="1">0.71</td></tr><tr><td rowspan="1" colspan="1">Low-density lipoprotein, mg/dL at the PET scan</td><td rowspan="1" colspan="1">124 (91, 191)</td><td rowspan="1" colspan="1">117 (66, 181)</td><td rowspan="1" colspan="1">120 (66, 166)</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">High-density lipoprotein, mg/dL at baseline</td><td rowspan="1" colspan="1">70 (45, 84)</td><td rowspan="1" colspan="1">70 (54, 89)</td><td rowspan="1" colspan="1">68 (50, 122)</td><td rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">High-density lipoprotein, mg/dL at the PET scan</td><td rowspan="1" colspan="1">64 (41, 98)</td><td rowspan="1" colspan="1">64 (39, 92)</td><td rowspan="1" colspan="1">58 (43, 131)</td><td rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">Triglycerides, mg/dL at baseline</td><td rowspan="1" colspan="1">68 (29, 229)</td><td rowspan="1" colspan="1">83 (33, 226)</td><td rowspan="1" colspan="1">72 (27, 233)</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Triglycerides, mg/dL at the PET scan</td><td rowspan="1" colspan="1">100 (62, 230)</td><td rowspan="1" colspan="1">83 (52, 204)</td><td rowspan="1" colspan="1">94 (59, 336)</td><td rowspan="1" colspan="1">0.60</td></tr><tr><td rowspan="1" colspan="1">Fasting Blood Glucose, mg/dL at baseline</td><td rowspan="1" colspan="1">76 (65, 100)</td><td rowspan="1" colspan="1">78 (67, 94)</td><td rowspan="1" colspan="1">78 (68, 94)</td><td rowspan="1" colspan="1">0.38</td></tr><tr><td rowspan="1" colspan="1">Fasting Blood Glucose, mg/dL at the PET scan</td><td rowspan="1" colspan="1">96 (88, 113)</td><td rowspan="1" colspan="1">93 (82, 108)</td><td rowspan="1" colspan="1">94 (75, 126)</td><td rowspan="1" colspan="1">0.59</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Unless otherwise indicated, data are given as the median (range). <sup>b</sup><italic>p</italic>-values are assessed using Kruskal Wallis and Fisher&#x02019;s Exact Tests. <sup>*</sup>Pairwise 
comparison to placebo <italic>p</italic>&#x0200a;&#x0003c;&#x0200a;0.05. Abbreviations: CEE: Conjugated equine estrogen; <italic>APOE</italic>: 
Apolipoprotein E</p></table-wrap-foot></table-wrap><table-wrap id="jad-53-jad160258-t002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Cognitive Test Scores at the time of PiB PET imaging</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Cognitive scores<sup>a</sup></td><td rowspan="1" colspan="1">Oral CEE (<italic>N</italic>&#x0200a;=&#x0200a;17)</td><td rowspan="1" colspan="1">Transdermal 17&#x003b2;-Estradiol (<italic>N</italic>&#x0200a;=&#x0200a;21)</td><td rowspan="1" colspan="1">Placebo (<italic>N</italic>&#x0200a;=&#x0200a;30)</td><td rowspan="1" colspan="1"><italic>p</italic>-values<sup>b</sup></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">NYU Paragraph Immediate Recall Total Score</td><td rowspan="1" colspan="1">25 (16, 33)</td><td rowspan="1" colspan="1">26 (15, 39)</td><td rowspan="1" colspan="1">24 (17, 40)</td><td rowspan="1" colspan="1">0.86</td></tr><tr><td rowspan="1" colspan="1">NYU Delayed Recall Total Score</td><td rowspan="1" colspan="1">16 (5, 24)</td><td rowspan="1" colspan="1">14 (7, 23)</td><td rowspan="1" colspan="1">14 (9, 32)</td><td rowspan="1" colspan="1">0.88</td></tr><tr><td rowspan="1" colspan="1">CVLT-II Trials 1&#x02013;3 Total Score</td><td rowspan="1" colspan="1">29 (16, 36)</td><td rowspan="1" colspan="1">33 (25, 42)</td><td rowspan="1" colspan="1">31 (14, 43)</td><td rowspan="1" colspan="1">0.03<sup>*</sup></td></tr><tr><td rowspan="1" colspan="1">CVLT-II Trial Short Delay Free Recall score</td><td rowspan="1" colspan="1">10 (3, 16)</td><td rowspan="1" colspan="1">12 (7, 16)</td><td rowspan="1" colspan="1">11 (4, 16)</td><td rowspan="1" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">CVLT-II Trial Long Delay Free Recall score</td><td rowspan="1" colspan="1">9 (3, 15)</td><td rowspan="1" colspan="1">11 (6, 15)</td><td rowspan="1" colspan="1">10 (4, 16)</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">WMS-III Digit Span Total Score</td><td rowspan="1" colspan="1">15 (10, 22)</td><td rowspan="1" colspan="1">18 (10, 26)</td><td rowspan="1" colspan="1">17 (8, 26)</td><td rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">WMS-III Letter Number Sequencing Trial Total Score</td><td rowspan="1" colspan="1">10 (6, 14)</td><td rowspan="1" colspan="1">11 (6, 15)</td><td rowspan="1" colspan="1">10 (7, 17)</td><td rowspan="1" colspan="1">0.50</td></tr><tr><td rowspan="1" colspan="1">Trail Making Test A (Time to complete in seconds)</td><td rowspan="1" colspan="1">24 (15, 44)</td><td rowspan="1" colspan="1">23 (15, 43)</td><td rowspan="1" colspan="1">24 (15, 39)</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">Trail Making Test B (Time to complete in seconds)</td><td rowspan="1" colspan="1">56 (33, 83)</td><td rowspan="1" colspan="1">59 (35, 249)</td><td rowspan="1" colspan="1">57 (33, 135)</td><td rowspan="1" colspan="1">0.85</td></tr><tr><td rowspan="1" colspan="1">Phonemic Fluency (F,A,S) Total Score</td><td rowspan="1" colspan="1">44 (27, 69)</td><td rowspan="1" colspan="1">43 (19, 59)</td><td rowspan="1" colspan="1">46 (22, 77)</td><td rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Semantic Fluency (animals, fruits, vegetables) Total Score</td><td rowspan="1" colspan="1">56 (30, 77)</td><td rowspan="1" colspan="1">55 (38, 68)</td><td rowspan="1" colspan="1">52 (36, 71)</td><td rowspan="1" colspan="1">0.35</td></tr><tr><td rowspan="1" colspan="1">Stroop Trial Word</td><td rowspan="1" colspan="1">99 (69, 136)</td><td rowspan="1" colspan="1">105 (70, 120)</td><td rowspan="1" colspan="1">100 (69, 140)</td><td rowspan="1" colspan="1">0.95</td></tr><tr><td rowspan="1" colspan="1">Stroop Trial Color</td><td rowspan="1" colspan="1">78 (61, 96)</td><td rowspan="1" colspan="1">74 (60, 110)</td><td rowspan="1" colspan="1">75 (58, 101)</td><td rowspan="1" colspan="1">0.55</td></tr><tr><td rowspan="1" colspan="1">Stroop Trial Color-Word</td><td rowspan="1" colspan="1">43 (18, 58)</td><td rowspan="1" colspan="1">44 (31, 61)</td><td rowspan="1" colspan="1">46 (21, 78)</td><td rowspan="1" colspan="1">0.78</td></tr><tr><td rowspan="1" colspan="1">Digit Symbol Total Score</td><td rowspan="1" colspan="1">82 (57, 93)</td><td rowspan="1" colspan="1">83 (61, 108)</td><td rowspan="1" colspan="1">82 (64, 103)</td><td rowspan="1" colspan="1">0.09</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Data shown are median (range) of raw scores. <sup>b</sup><italic>p</italic>-values were assessed 
using Analysis of Variance adjusting for age at PiB PET, levels of education, time from menopause to 
randomization (months) and APOE <italic>&#x0025b;</italic>4 carrier status. <sup>*</sup>Tukey Honest significant 
differences test for <italic>post hoc</italic> comparisons: Oral CEE versus placebo (<italic>p</italic>&#x0200a;=&#x0200a;0.03); CEE versus 
transdermal17&#x003b2;-estradiol (<italic>p</italic>&#x0200a;=&#x0200a;0.08); transdermal17&#x003b2;-estradiol versus placebo 
(<italic>p</italic>&#x0200a;=&#x0200a;0.98).</p></table-wrap-foot></table-wrap></floats-group></article>